Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKinsey
Novartis
Dow
UBS
US Army
AstraZeneca
Cantor Fitzgerald
Medtronic

Generated: October 18, 2017

DrugPatentWatch Database Preview

XIMINO Drug Profile

« Back to Dashboard

Which patents cover Ximino, and what generic Ximino alternatives are available?

Ximino is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. There are seven patents protecting this drug.

This drug has thirteen patent family members in ten countries.

The generic ingredient in XIMINO is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

Summary for Tradename: XIMINO

US Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list26
Patent Applications: see list1,589
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:XIMINO at DailyMed

Pharmacology for Tradename: XIMINO

Ingredient-typeTetracyclines
Drug ClassTetracycline-class Drug
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-001Jul 11, 2012RXNoNo► Subscribe► Subscribe ► Subscribe
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-005Jul 11, 2012RXNoNo► Subscribe► Subscribe ► Subscribe
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-001Jul 11, 2012RXNoNo► Subscribe► SubscribeY ► Subscribe
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-001Jul 11, 2012RXNoNo► Subscribe► Subscribe ► Subscribe
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-003Jul 11, 2012RXNoNo► Subscribe► Subscribe ► Subscribe
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-005Jul 11, 2012RXNoNo► Subscribe► Subscribe ► Subscribe
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-002Jul 11, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-005Jul 11, 2012RXNoNo► Subscribe► Subscribe ► Subscribe
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-004Jul 11, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe
Sun Pharm Inds Ltd
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL201922-003Jul 11, 2012RXNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: XIMINO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,722,650Extended-release minocycline dosage forms► Subscribe
9,192,615Method for the treatment of acne and certain dosage forms thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: XIMINO

Country Document Number Estimated Expiration
Japan2013213047► Subscribe
Israel188331► Subscribe
South Africa200802064► Subscribe
World Intellectual Property Organization (WIPO)2007001961► Subscribe
Norway20080444► Subscribe
European Patent Office1898925► Subscribe
Canada2613273► Subscribe
Australia2006262428► Subscribe
Japan5744976► Subscribe
World Intellectual Property Organization (WIPO)2010017310► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Deloitte
Harvard Business School
Medtronic
Boehringer Ingelheim
US Army
McKesson
Fuji
Express Scripts
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot